• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Will Advanced Micro Devices Follow NVIDIA Higher?

By: MarketBeat
March 21, 2023 at 06:45 AM EDT
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

 Advanced Micro Devices stock price

The entire chip sector shows a bottom and is on the cusp of reversal, with NVIDIA (NASDAQ: NVDA)  in the lead. The company’s Q4 results were better than expected due to unexpected strengths that led to solid guidance. The stock is up about 150% from its latest bottom and on track to hit higher highs this year. The move is partly driven by the analysts lending support to the market. In the case of NVIDIA, its stock has received 2 dozen analyst updates that have it breaking out of a Head & Shoulders Reversal and ready to tackle the next resistance point near $275. 

The 36 analysts rating NVIDIA have it pegged at a Moderate Buy with a price target trending higher than last quarter and last month. The caveat is that the consensus has the stock trading at fair value at its current levels, but the trend points to higher levels. The latest update comes from Robert W. Baird, who upped its target to $300. That is a full 21% above the current consensus and has the stock trading above its next resistance point. Citigroup and Morgan Stanley both see another few hundred basis points of upside on top of that. 

NVIDIA Up On AI, Next-Gen: Gains Will Be Capped 

The risk for NVIDIA shareholders is the outlook. The outlook is good, undoubtedly less bad than it could have been, but the company is still expecting a 20% decline in revenue for the current quarter. The strength in Q4 was driven by a shift to next-gen technologies and not so much by end-user demand, so there is a chance the weakness could persist through the end of the fiscal year. 

AMD’s (NASDAQ: AMD) results weren’t better than NVIDIA’s and may fall into the “worse” column. The takeaway is that the analysts had secretly feared even worse than the company reported, which has put a bottom in the share prices. The results were driven by AMD’s diversification which is expected to continue supporting business this year. The Data Center and Embedded segments will offset weakness in Client and Gaming, resulting in a 10% YOY decline in revenue for the current quarter. 

The analyst reaction was favorable, so there is a chance the market could follow NVDA up to retest resistance at higher levels. The 30 analysts produced 11 updates that confirmed the consensus price target. The stock is pegged at a Moderate Buy with a price target that assumes fair value at current levels. The caveat is the same as with NVIDIA; the latest updates have the stock trading closer to $115 or about 25% above the current price action. Raymond James analyst Srini Pajjuri views the chip market as mixed with strengths and weaknesses depending on the end market. 

NVIDIA Broke Out: Will AMD Follow Suit 

The price action in NVIDIA has been textbook over the last 3 months. The stock moved down to a low, confirmed a bottom, traced out a Head & Shoulders pattern, and then broke out of it. This has the stock on track to reach new highs, and AMD is right behind. So far, this market has formed the Head & Shoulders bottom but has yet to confirm the reversal A move above the neckline near $100 would confirm the reversal and bring targets near $140 into play. 

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More
News headline image
Amgen Touts MariTide, AI Gains and 2026 Growth Plans at Jefferies Conference ↗
Today 1:02 EDT
Via MarketBeat
Topics Artificial Intelligence ETFs
Tickers AMGN
News headline image
Alvotech Nears Inflection Point With 5 U.S. Biosimilars Targeted by Year-End ↗
Today 0:02 EDT
Via MarketBeat
Tickers ALVO
News headline image
Altimmune Touts Pemvidutide Momentum Ahead of Phase 3 MASH Trial ↗
June 04, 2026
Via MarketBeat
Tickers ALT
News headline image
Align Technology CFO: Global Growth, DSOs Offset North America Demand Pressure ↗
June 04, 2026
Via MarketBeat
Topics Earnings Economy
Tickers ALGN
News headline image
Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break Moment ↗
June 04, 2026
Via MarketBeat
Tickers ALDX

Recent Quotes

View More
Symbol Price Change (%)
AMZN  253.79
+0.00 (0.00%)
AAPL  311.23
+0.00 (0.00%)
AMD  523.20
+0.00 (0.00%)
BAC  54.17
+0.00 (0.00%)
GOOG  369.27
+0.00 (0.00%)
META  627.57
+0.00 (0.00%)
MSFT  428.05
+0.00 (0.00%)
NVDA  218.66
+0.00 (0.00%)
ORCL  236.34
+0.00 (0.00%)
TSLA  418.45
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap